Corvus – a mAb targeting oncology and immune disorders
Corvus is a small biotech developing precision medicines, primarily for oncology patients. It came to Lonza seeking to develop a monoclonal antibody called CPI06, now known as Mupadolimab. This inhibits the production of adenosine in the tumor microenvironment and has an agonistic effect on B cells.
When considering CDMOs for CPI06, Corvus was aware of Lonza’s platform methodology, custom built for mAbs, and its track record commercializing antibodies. Lonza welcomed Corvus and demonstrated flexibility taking on the project by starting work with available capacity in Singapore and then transferring to Slough, UK. Multiple consistent batches were manufactured, and the product is currently in clinical trials with CMC work simultaneously taking place to provide a good regulatory platform with a goal for commercialization.